Zura Bio Limited Class A Ordinary Shares (ZURA)

A director of Zura Bio (NASDAQ: ZURA), Someit Sidhu, intends to sell 50,000 common shares valued at $287,712.50, originating from a stock option exercise, on August 18, 2026. This planned sale follows several prior sales of ZURA common stock by the same individual within the last three months. The filing, a Form 144, indicates the transaction will be handled by Morgan Stanley Smith Barney LLC.

An affiliate of Zura Bio (NASDAQ: ZURA), Someit Sidhu, has filed a Form 144 indicating a planned sale of 27,000 shares of ZURA common stock on or about August 17, 2026. This sale will be executed for cash through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, following a stock option exercise. The filing also reports prior sales by Sidhu within the last three months, totaling 40,000 shares on August 14, 2026, and 51,000 shares on August 13, 2026, for respective amounts.

This article reports on an SEC Form 144 filing by Zura Bio Ltd on August 13, 2026. The filing indicates a proposed sale of 51,000 shares of common stock, acquired through a stock option exercise, with an aggregate market value of $287,043.30, to be executed through Morgan Stanley Smith Barney LLC. The document details the filer and issuer information, as well as the securities to be sold and their acquisition method.

Zura Bio announced the completion of enrollment for its Phase 2 TibuSHIELD study in hidradenitis suppurativa (HS) with 247 participants and the TibuSURE study in systemic sclerosis (SSc) with 91 participants, both exceeding initial targets. The company also reported its Q2 2026 financial results, holding $205.1 million in cash, which is expected to fund operations through the end of 2028, and plans to initiate a new Phase 2 study for tibulizumab in polymyalgia rheumatica (PMR) by year-end 2026. Topline data for TibuSHIELD is expected in Q4 2026, and for TibuSURE in H1 2027.

Zura Bio Limited has released an updated corporate presentation dated July 1, 2026, for upcoming investor meetings and conferences. This presentation, furnished as Exhibit 99.1 to a Form 8-K filing, details the company's lead program, tibulizumab, a bispecific antibody targeting IL-17 and BAFF pathways for complex immune disorders like hidradenitis suppurativa (HS) and systemic sclerosis (SSc). The company anticipates topline data from Phase 2 studies for HS and SSc in Q4 2026 and 1H 2027, respectively, and plans to initiate a third Phase 2 study by year-end 2026, backed by a strong cash position.